PIP5K1A and neoplasm: Furthermore, we demonstrated that the combination of MakA with the PIP5K1α inhibitor ISA-2011B caused a more significant decrease in tumour cell proliferation when compared to HCT8 cells treated with MakA or ISA-2011B alone.